Telix Pharmaceuticals (TLX) Non-Current Debt (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Non-Current Debt for 3 consecutive years, with $391.9 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 8.6% to $391.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $391.9 million through Dec 2025, up 8.6% year-over-year, with the annual reading at $391.9 million for FY2025, 14.66% up from the prior year.
  • Non-Current Debt for Q4 2025 was $391.9 million at Telix Pharmaceuticals, up from $360.9 million in the prior quarter.
  • The five-year high for Non-Current Debt was $391.9 million in Q4 2025, with the low at $5.3 million in Q4 2023.
  • Average Non-Current Debt over 3 years is $252.7 million, with a median of $360.9 million recorded in 2024.
  • The sharpest move saw Non-Current Debt surged 6652.77% in 2024, then increased 8.6% in 2025.
  • Over 3 years, Non-Current Debt stood at $5.3 million in 2023, then soared by 6652.77% to $360.9 million in 2024, then rose by 8.6% to $391.9 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $391.9 million, $360.9 million, and $5.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.